Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SARS-CoV-2 vaccine response in primary Sjögren's syndrome
NL-OMON51179Phase 4Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Apr 2021
- Countries
- 1
01
Overview
Phase 4, open-label trial of SARS-CoV-2 vaccine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Primary antibody-based immune response. Started Apr 2021; status: active, not recruiting.
02
Drugs
SARS-CoV-2 vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON51179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51179.